DI-088 Everolimus in tuberous sclerosis complex treatment

• Published in: European journal of hospital pharmacy. Science and practice Vol. 23; no. Suppl 1; p. A157
• Main Authors: Gasque, MP Monforte, Fraile, R Rodil, Elizondo, M Castresana, Valencia, M Gutiérrez, Fabo, E Lacalle, González, J Fernández, Garrastatxu, I Monteserin, Uriz, M Etxeberria, Carricas, M Sarobe
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.03.2016
• Subjects: Inhibitor drugs; Patients

BackgroundTuberous sclerosis complex (TSC) is an autosomal dominant disease with variable expressiveness and multisystem involvement. Everolimus, an mTOR inhibitor, is indicated for the treatment of kidney angiomyolipoma and subependymal giant cell astrocytoma (SEGA) associated with TSC.PurposeThe o...